David Liu
About David Liu
David Liu, Chief Medical Officer at Nuvation Bio
David Liu joined Nuvation Bio as Chief Medical Officer in 2022. With over 20 years of experience in leading the discovery and development of oncology therapies, Liu brings extensive expertise and a strong track record to his role. His focus at Nuvation Bio involves advancing the company's oncology pipeline and overseeing clinical development.
David Liu's Educational Background
David Liu holds a Ph.D. from the Massachusetts Institute of Technology and an M.S. from the University of Toledo. He earned his M.D. from Beijing Medical University, now known as Peking University School of Medicine. This robust educational background has laid the foundation for his career in medical research and clinical development, particularly in the field of oncology.
David Liu's Experience in Oncology Therapy Development
David Liu has more than two decades of experience leading oncology therapy discovery and development. He has built and led comprehensive clinical R&D organizations, including global clinical research, clinical operations, pharmacovigilance, biostatistics, programming and data management, clinical pharmacology, and drug supply. His extensive experience underscores his capability in driving forward oncology projects at Nuvation Bio.
David Liu's Previous Roles in Biotechnology and Pharmaceuticals
Before joining Nuvation Bio, David Liu served as the Chief Medical Officer at a biotechnology company based in Shanghai, China. Prior to that, he held several strategic roles at Bristol Myers Squibb, where he led the Global Prostate Cancer Program and Pediatric Clinical Development, and contributed to the Translational Research of ipilimumab. Additionally, Liu was the Global Lead Physician at Celgene, overseeing the revlimid plus rituximab submission program in indolent lymphoma.
David Liu's Involvement in Key Oncology Programs
David Liu has played a critical role in the development of key oncology programs. At Bristol Myers Squibb, he was involved in the development of nivolumab and ipilimumab for China. His leadership in these high-impact programs highlights his contributions to advancing cancer treatments on a global scale.